TW200942537A - Compounds and compositions as kinase inhibitors - Google Patents

Compounds and compositions as kinase inhibitors

Info

Publication number: TW200942537A
Authority: TW; Taiwan
Prior art keywords: compounds; compositions; kinase inhibitors; fms; trkc
Prior art date: 2008-02-01

Application number

TW098102252A

Other languages

English (en)

Inventor

Barun Okram

Tetsuo Uno

Qiang Ding

ya-hua Liu

Yun-Ho Jin

qi-hui Jin

Jian-Wei Che

S Frank Yan

Xu Wu

Xue-Shi Hao

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-01

Filing date

2009-01-21

Publication date

2009-10-16

2009-01-21 Application filed by Irm Llc filed Critical Irm Llc

2009-10-16 Publication of TW200942537A publication Critical patent/TW200942537A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

TW098102252A 2008-02-01 2009-01-21 Compounds and compositions as kinase inhibitors TW200942537A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2566508P	2008-02-01	2008-02-01
US5309108P	2008-05-14	2008-05-14

Publications (1)

Publication Number	Publication Date
TW200942537A true TW200942537A (en)	2009-10-16

Family

ID=40474739

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW098102252A TW200942537A (en)	2008-02-01	2009-01-21	Compounds and compositions as kinase inhibitors
TW098102243A TW200938542A (en)	2008-02-01	2009-01-21	Compounds and compositions as kinase inhibitors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW098102243A TW200938542A (en)	2008-02-01	2009-01-21	Compounds and compositions as kinase inhibitors

Country Status (17)

Country	Link
US (2)	US8546370B2 (zh)
EP (2)	EP2250169A1 (zh)
JP (2)	JP2011511779A (zh)
KR (2)	KR20100118989A (zh)
CN (2)	CN101990539A (zh)
AR (2)	AR070521A1 (zh)
AU (2)	AU2009210517B2 (zh)
BR (1)	BRPI0906973A2 (zh)
CA (2)	CA2713807A1 (zh)
CL (1)	CL2009000200A1 (zh)
EA (2)	EA201001236A1 (zh)
MX (2)	MX2010008418A (zh)
PA (2)	PA8814301A1 (zh)
PE (2)	PE20091408A1 (zh)
TW (2)	TW200942537A (zh)
UY (2)	UY31624A1 (zh)
WO (2)	WO2009097287A1 (zh)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1213698B (it) *	1987-10-09	1989-12-29	Marposs Spa	Apparecchio a grande campo per il controllo di dimensioni lineari di pezzi
TW201105669A (en) *	2009-07-30	2011-02-16	Irm Llc	Compounds and compositions as Syk kinase inhibitors
JP2013501002A (ja) *	2009-07-30	2013-01-10	アイアールエム・リミテッド・ライアビリティ・カンパニー	Ｓｙｋキナーゼ阻害剤としての化合物および組成物
US20120245344A1 (en) *	2009-08-31	2012-09-27	Nippon Chemiphar Co., Ltd.	Gpr119 agonist
US8404677B2 (en) *	2009-10-29	2013-03-26	Genosco	Kinase inhibitors
US8440689B2 (en) *	2009-12-23	2013-05-14	Takeda Pharmaceutical Company Limited	Fused heteroaromatic pyrrolidinones
GB201007203D0 (en) *	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
SMT201900203T1 (it)	2010-05-20	2019-05-10	Array Biopharma Inc	Composti macrociclici come inibitori di trk chinasi
CN103415516A (zh) *	2011-01-21	2013-11-27	Abbvie公司	Alk的双环抑制剂
CN103384669A (zh) *	2011-01-21	2013-11-06	Abbvie公司	Alk的二环抑制剂
WO2012097479A1 (en) *	2011-01-21	2012-07-26	Abbott Laboratories	Bicyclic inhibitors of anaphastic lymphoma kinase
EP2683716A1 (en) *	2011-03-11	2014-01-15	Glaxo Group Limited	Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US8673905B2 (en) *	2011-03-17	2014-03-18	Hoffmann-La Roche Inc.	Imidazo pyrazines
KR20140028062A (ko)	2011-05-10	2014-03-07	머크 샤프 앤드 돔 코포레이션	Syk 억제제로서의 아미노피리미딘
US9120785B2 (en)	2011-05-10	2015-09-01	Merck Sharp & Dohme Corp.	Pyridyl aminopyridines as Syk inhibitors
WO2012154518A1 (en)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Bipyridylaminopyridines as syk inhibitors
WO2012167423A1 (en) *	2011-06-08	2012-12-13	Hutchison Medipharma Limited	Substituted pyridopyrazines as novel syk inhibitors
EP2729463B1 (en) *	2011-07-08	2015-07-29	Sanofi	Substituted phenyl compounds
CN103974955B (zh)	2011-08-23	2018-06-19	阿萨纳生物科技有限责任公司	嘧啶并-哒嗪酮化合物及其用途
WO2013033981A1 (zh) *	2011-09-06	2013-03-14	江苏先声药物研究有限公司	一类2,7-萘啶衍生物及其制备方法和应用
CN103159757B (zh) *	2011-12-09	2016-04-20	江苏先声药物研究有限公司	一类2,7-萘啶-1(2h)-酮的合成方法
WO2013052394A1 (en)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2013052393A1 (en)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013052391A1 (en)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013086208A1 (en) *	2011-12-06	2013-06-13	Confluence Life Sciences, Inc.	Substituted pyrimidinone-phenyl-pyrimidinyl compounds
CN103183674B (zh) *	2011-12-31	2017-09-12	江苏先声药业有限公司	一类稠杂环衍生物及其应用
US20140350034A1 (en) *	2012-01-27	2014-11-27	Novartis Ag	Aminopyridine derivatives as plasma kallikrein inhibitors
ES2694223T3 (es) *	2012-03-22	2018-12-19	Oscotec, Inc.	Compuestos de piridopirimidina y su uso como inhibidores de FLT3
WO2013192128A1 (en)	2012-06-20	2013-12-27	Merck Sharp & Dohme Corp.	Imidazolyl analogs as syk inhibitors
EP2863914B1 (en)	2012-06-20	2018-10-03	Merck Sharp & Dohme Corp.	Pyrazolyl derivatives as syk inhibitors
WO2013192098A1 (en)	2012-06-22	2013-12-27	Merck Sharp & Dohme Corp.	SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9416111B2 (en)	2012-06-22	2016-08-16	Merck Sharp & Dohme Corp.	Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
IN2015DN00950A (zh)	2012-08-13	2015-06-12	Novartis Ag
WO2014031438A2 (en)	2012-08-20	2014-02-27	Merck Sharp & Dohme Corp.	SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en)	2012-09-28	2017-03-07	Merck Sharp & Dohme Corp.	Triazolyl derivatives as Syk inhibitors
US8568747B1 (en)	2012-10-05	2013-10-29	Silvergate Pharmaceuticals, Inc.	Enalapril compositions
CN104854101B (zh)	2012-11-06	2018-05-01	上海复尚慧创医药研究有限公司	Alk激酶抑制剂
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
WO2014086032A1 (en) *	2012-12-07	2014-06-12	Hutchison Medipharma Limited	Substituted pyridopyrazines as syk inhibitors
US9624210B2 (en)	2012-12-12	2017-04-18	Merck Sharp & Dohme Corp.	Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
EP2935253B1 (en)	2012-12-21	2018-08-01	Zenith Epigenetics Ltd.	Novel heterocyclic compounds as bromodomain inhibitors
EP2934525B1 (en)	2012-12-21	2019-05-08	Merck Sharp & Dohme Corp.	Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9499534B2 (en)	2013-04-26	2016-11-22	Merck Sharp & Dohme Corp.	Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
EP2988744A4 (en)	2013-04-26	2016-11-02	Merck Sharp & Dohme	THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR
EP3010918B1 (en)	2013-06-21	2018-08-15	Zenith Epigenetics Ltd.	Novel substituted bicyclic compounds as bromodomain inhibitors
SI3010503T1 (sl)	2013-06-21	2020-07-31	Zenith Epigenetics Ltd.	Novi biciklični inhibitorji bromodomene
JP6542212B2 (ja)	2013-07-31	2019-07-10	ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＬｔｄ．	ブロモドメイン阻害剤としての新規キナゾリノン
EP3082807B1 (en)	2013-12-20	2018-07-04	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9670196B2 (en)	2013-12-20	2017-06-06	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
WO2015095445A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
TWI735853B (zh)	2013-12-23	2021-08-11	美商克洛諾斯生技有限公司	脾酪胺酸激酶抑制劑
CN104788449B (zh) *	2014-01-22	2017-03-22	四川大学	3和6位取代的1,8萘啶‑4‑酮衍生物及其制备方法和用途
US9775839B2 (en)	2014-03-13	2017-10-03	Merck Sharp & Dohme Corp.	2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
WO2015146928A1 (ja) *	2014-03-24	2015-10-01	武田薬品工業株式会社	複素環化合物
HK1246273B (zh)	2014-12-01	2019-12-06	恒翼生物医药(上海)股份有限公司	作为溴域抑制剂的取代吡啶
CA2966298A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
CA2966449A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Ltd.	Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en)	2014-12-17	2018-07-18	Zenith Epigenetics Ltd.	Inhibitors of bromodomains
KR101845931B1 (ko) *	2015-06-18	2018-04-05	한국화학연구원	헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
WO2016204429A1 (ko) *	2015-06-18	2016-12-22	한국화학연구원	헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물.
SI3322706T1 (sl)	2015-07-16	2021-04-30	Array Biopharma, Inc.	Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
US10370129B2 (en) *	2015-08-17	2019-08-06	Dash Llc	Assemblies including plug devices, and related plug devices and methods
CN105130986B (zh) *	2015-09-30	2017-07-18	广州科擎新药开发有限公司	嘧啶或吡啶并吡啶酮类化合物及其应用
US9463183B1 (en) *	2015-10-30	2016-10-11	Silvergate Pharmaceuticals, Inc.	Lisinopril formulations
US9669008B1 (en)	2016-03-18	2017-06-06	Silvergate Pharmaceuticals, Inc.	Enalapril formulations
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
CA3049136C (en)	2017-01-18	2022-06-14	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR20190140011A (ko)	2017-04-28	2019-12-18	아사나 바이오사이언시스 엘엘씨	아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
JP7299167B2 (ja) *	2017-06-14	2023-06-27	チアタイティエンチンファーマシューティカルグループカンパニーリミテッド	Ｓｙｋ阻害薬及びその使用方法
TWI876442B (zh)	2017-10-10	2025-03-11	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN107961235B (zh) *	2017-12-27	2019-09-24	湖北工业大学	芳香酯化合物wy124用于制备抗adv-7病毒的药物
JP6997876B2 (ja)	2018-01-18	2022-02-04	アレイバイオファーマインコーポレイテッド	Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
US11524963B2 (en)	2018-01-18	2022-12-13	Array Biopharma Inc.	Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
EP3740491A1 (en)	2018-01-18	2020-11-25	Array Biopharma, Inc.	Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US10100054B1 (en)	2018-04-03	2018-10-16	King Saud University	Pyrido[2,3-d]pyrimidines as anticancer agents
JP7637049B2 (ja)	2018-08-13	2025-02-27	エフ．ホフマン－ラロシュアーゲー	モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物
AU2019322161A1 (en) *	2018-08-13	2020-11-12	F. Hoffmann-La Roche Ag	New heterocyclic compounds as monoacylglycerol lipase inhibitors
ES2922314T3 (es)	2018-09-10	2022-09-13	Array Biopharma Inc	Compuestos heterocíclicos condensados como inhibidores de cinasa RET
CN112771042A (zh) *	2018-09-28	2021-05-07	重庆复创医药研究有限公司	作为蛋白激酶抑制剂的萘啶酮和吡啶基嘧啶酮类化合物
EP4371987B9 (en)	2018-10-31	2025-11-26	Gilead Sciences, Inc.	Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko)	2018-10-31	2024-04-19	길리애드 사이언시즈, 인코포레이티드	Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
CN113950479A (zh)	2019-02-22	2022-01-18	克洛诺斯生物股份有限公司	作为syk抑制剂的缩合吡嗪的固体形式
CN111961035B (zh) *	2019-05-20	2022-11-01	南京科技职业学院	一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
WO2020237025A1 (en)	2019-05-23	2020-11-26	Gilead Sciences, Inc.	Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CA3151516A1 (en)	2019-09-12	2021-03-18	F. Hoffmann-La Roche Ag	4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
CN112824420B (zh) *	2019-11-21	2022-04-26	浙江同源康医药股份有限公司	用作egfr激酶抑制剂的化合物及其应用
WO2021201574A1 (ko) *	2020-03-31	2021-10-07	보령제약 주식회사	Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물
MX2022013838A (es) *	2020-05-04	2023-02-22	Amgen Inc	Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso.
EP4174067B1 (en) *	2020-06-30	2025-11-05	Boryung Corporation	Method for preparing compound as pi3k inhibitor and intermediate compound for preparing same
CN117120090A (zh) *	2021-02-12	2023-11-24	林伯士萨顿公司	Hpk1拮抗剂和其用途
EP4313989A4 (en)	2021-03-29	2025-03-05	Nimbus Saturn, Inc.	HPK1 ANTAGONISTS AND USES THEREOF
TWI825637B (zh)	2021-03-31	2023-12-11	美商輝瑞股份有限公司	啶－１，６（２ｈ，７ｈ）－二酮
CN116063329A (zh) *	2021-10-29	2023-05-05	北京望实智慧科技有限公司	Hpk1抑制剂、制备方法及其用途
CN118434727A (zh) *	2021-12-31	2024-08-02	上海海雁医药科技有限公司	取代的嘧啶酮衍生物、其药物组合物及医药上的用途
WO2023193759A1 (en) *	2022-04-07	2023-10-12	Insilico Medicine Ip Limited	Hpk1 antagonists and uses thereof
WO2023208127A1 (zh) *	2022-04-27	2023-11-02	南京明德新药研发有限公司	杂芳基取代的双环化合物及其应用
WO2023209084A1 (en) *	2022-04-28	2023-11-02	Astrazeneca Ab	Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) *	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their use in the treatment of cancer
JP2024047569A (ja) *	2022-09-26	2024-04-05	ファイザー・インク	Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
WO2024217587A1 (zh) *	2023-04-21	2024-10-24	南京正大天晴制药有限公司	具有axl抑制活性的取代吡嗪化合物
WO2024233847A2 (en) *	2023-05-10	2024-11-14	Vigil Neuroscience, Inc.	Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
CN116813608B (zh) *	2023-06-08	2024-03-22	英矽智能科技(上海)有限公司	噻唑类化合物及其应用
CN117327067B (zh) *	2023-08-14	2025-11-18	天津医科大学总医院	一种小分子化合物epic-1042、药物组合物及其制备方法和应用
WO2025264837A1 (en) *	2024-06-20	2025-12-26	Lieber Institute, Inc.	Naphthyridine gpr52 modulators and methods of use thereof
WO2025262192A1 (en) *	2024-06-21	2025-12-26	Breakpoint Therapeutics Gmbh	Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5654307A (en) *	1994-01-25	1997-08-05	Warner-Lambert Company	Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US20030158195A1 (en)	2001-12-21	2003-08-21	Cywin Charles L.	1,6 naphthyridines useful as inhibitors of SYK kinase
TW200413381A (en)	2002-11-04	2004-08-01	Hoffmann La Roche	Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
MXPA06001098A (es) *	2003-07-29	2006-04-24	Irm Llc	Compuestos y composiciones utiles como inhibidores de proteina cinasa.
JP4758349B2 (ja) *	2003-10-08	2011-08-24	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
KR100781704B1 (ko)	2005-04-20	2007-12-03	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
EP1960372B1 (en) *	2005-12-15	2015-12-09	Rigel Pharmaceuticals, Inc.	Kinase inhibitors and their uses
JP2009530342A (ja) *	2006-03-20	2009-08-27	エフ．ホフマン−ラロシュアーゲー	Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法
EP2018167A4 (en)	2006-05-15	2010-07-14	Irm Llc	COMPOSITIONS AND METHODS AS INHIBITORS OF FGF RECEPTOR KINASES
KR20080091948A (ko)	2007-04-10	2008-10-15	에스케이케미칼주식회사	락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물

2009
- 2009-01-21 TW TW098102252A patent/TW200942537A/zh unknown
- 2009-01-21 TW TW098102243A patent/TW200938542A/zh unknown
- 2009-01-27 CA CA2713807A patent/CA2713807A1/en not_active Abandoned
- 2009-01-27 MX MX2010008418A patent/MX2010008418A/es not_active Application Discontinuation
- 2009-01-27 JP JP2010545082A patent/JP2011511779A/ja active Pending
- 2009-01-27 AU AU2009210517A patent/AU2009210517B2/en not_active Ceased
- 2009-01-27 WO PCT/US2009/032148 patent/WO2009097287A1/en not_active Ceased
- 2009-01-27 US US12/865,339 patent/US8546370B2/en not_active Expired - Fee Related
- 2009-01-27 CN CN2009801118648A patent/CN101990539A/zh active Pending
- 2009-01-27 US US12/865,367 patent/US8354526B2/en not_active Expired - Fee Related
- 2009-01-27 AU AU2009209304A patent/AU2009209304B2/en not_active Ceased
- 2009-01-27 WO PCT/US2009/032127 patent/WO2009099801A1/en not_active Ceased
- 2009-01-27 KR KR1020107019403A patent/KR20100118989A/ko not_active Abandoned
- 2009-01-27 MX MX2010008421A patent/MX2010008421A/es not_active Application Discontinuation
- 2009-01-27 JP JP2010545085A patent/JP2011510990A/ja active Pending
- 2009-01-27 CA CA2711937A patent/CA2711937A1/en not_active Abandoned
- 2009-01-27 EA EA201001236A patent/EA201001236A1/ru unknown
- 2009-01-27 EP EP09708389A patent/EP2250169A1/en not_active Withdrawn
- 2009-01-27 CN CN2009801121388A patent/CN101983198A/zh active Pending
- 2009-01-27 EP EP09705446A patent/EP2238137A1/en not_active Withdrawn
- 2009-01-27 BR BRPI0906973-9A patent/BRPI0906973A2/pt not_active IP Right Cessation
- 2009-01-27 KR KR1020107019402A patent/KR20100110888A/ko not_active Ceased
- 2009-01-27 EA EA201001238A patent/EA201001238A1/ru unknown
- 2009-01-30 AR ARP090100302A patent/AR070521A1/es unknown
- 2009-01-30 PA PA20098814301A patent/PA8814301A1/es unknown
- 2009-01-30 AR ARP090100303A patent/AR070522A1/es unknown
- 2009-01-30 PE PE2009000142A patent/PE20091408A1/es not_active Application Discontinuation
- 2009-01-30 PE PE2009000140A patent/PE20091562A1/es not_active Application Discontinuation
- 2009-01-30 PA PA20098814401A patent/PA8814401A1/es unknown
- 2009-01-30 CL CL2009000200A patent/CL2009000200A1/es unknown
- 2009-02-02 UY UY031624A patent/UY31624A1/es not_active Application Discontinuation
- 2009-02-02 UY UY031623A patent/UY31623A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20100118989A (ko)	2010-11-08
CN101983198A (zh)	2011-03-02
EA201001238A1 (ru)	2011-04-29
AR070522A1 (es)	2010-04-14
AU2009209304B2 (en)	2012-04-12
PE20091408A1 (es)	2009-10-19
WO2009097287A9 (en)	2009-10-01
US20110003798A1 (en)	2011-01-06
JP2011510990A (ja)	2011-04-07
WO2009099801A1 (en)	2009-08-13
US8354526B2 (en)	2013-01-15
CA2713807A1 (en)	2009-08-06
EP2250169A1 (en)	2010-11-17
UY31623A1 (es)	2009-08-31
US8546370B2 (en)	2013-10-01
AU2009210517B2 (en)	2012-05-24
PA8814301A1 (es)	2010-05-26
UY31624A1 (es)	2009-08-31
PA8814401A1 (es)	2010-05-26
US20110003790A1 (en)	2011-01-06
PE20091562A1 (es)	2009-11-03
EA201001236A1 (ru)	2011-02-28
WO2009097287A8 (en)	2010-08-12
EP2238137A1 (en)	2010-10-13
AR070521A1 (es)	2010-04-14
AU2009209304A1 (en)	2009-08-06
KR20100110888A (ko)	2010-10-13
CL2009000200A1 (es)	2010-09-10
WO2009097287A1 (en)	2009-08-06
CA2711937A1 (en)	2009-08-13
JP2011511779A (ja)	2011-04-14
AU2009210517A1 (en)	2009-08-13
MX2010008421A (es)	2011-01-14
TW200938542A (en)	2009-09-16
MX2010008418A (es)	2010-08-23
BRPI0906973A2 (pt)	2015-07-14
CN101990539A (zh)	2011-03-23

Publication	Publication Date	Title
TW200942537A (en)	2009-10-16	Compounds and compositions as kinase inhibitors
WO2009140128A3 (en)	2010-01-07	Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
MX2009006170A (es)	2009-06-19	Compuestos y composiciones como inhibidores de cinasa.
GEP20156251B (en)	2015-02-25	Compounds and methods for kinase modulation, and indications therefor
MX2009011951A (es)	2009-12-11	Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2010009207A (es)	2011-03-03	Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
TN2009000163A1 (en)	2010-10-18	Compounds and compositions as protein kinase inibitors
PH12014500281A1 (en)	2015-09-07	Compounds as tyrosine kinase modulators
MX2012001070A (es)	2012-03-16	Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
MX2009010984A (es)	2010-01-15	Moduladores de heterociclo cinasa de anillo fusionado.
ATE544761T1 (de)	2012-02-15	Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
TN2012000081A1 (en)	2013-09-19	Compounds and compositions as protein kinase inhibitors
MY148851A (en)	2013-06-14	Dihydropyridine derivatives as useful as protein kinase inhibitors
PH12015501955B1 (en)	2018-03-19	Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2009011952A (es)	2009-12-11	Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2010004309A (es)	2010-05-03	Moduladores de piperidinil y piperazinil de gamma-secretasa.
MX2011008126A (es)	2011-08-17	Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.
TN2010000519A1 (en)	2012-05-24	Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
TN2011000668A1 (en)	2013-05-24	Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders